What neoadjuvant chemotherapy regimen would you choose for a young patient with HER2 positive breast cancer with reduced ejection fraction?

TCH or TCHP are both well-accepted non-anthracycline regimens; the benefit of pertuzumab is small so would omit unless the disease is very high risk. The issue of using any HER2-directed therapy in this setting depends upon the severity of the EF decrease (if minor may be able to manage with cardiol...